About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.
Category Archives: OPDP
FDA’s OPDP Issues Two New Untitled Letters
While enforcement has been at a low ebb for quite some time with FDA’s Office of Prescription Drug Promotion (OPDP), this week took a different turn with the posting of two new untitled letters sent October 31. That brings the … Continue reading
Posted in OPDP, Regulatory Communications
Tagged #OPDP, #pharma, FDA
Comments Off on FDA’s OPDP Issues Two New Untitled Letters
What Happens When You Talk About Adherence in Promotional Communications?
FDA has announced that the Office of Prescription Drug Promotion (OPDP) is planning a study to evaluate the influence that statements made in a promotional communication about patient adherence to a medication may have on the resulting preference for a … Continue reading